Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Current Liabilities
All obligations due within one year.
Alumis Inc. Common StockNASDAQ: ALMS
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities falls 10.9% from a year ago
Total current liabilities stood at $76.23M at the end of Q2 FY2026, down 10.9% from a year earlier and up 7.5% from the prior quarter. Over 3 fiscal years it compounded at +76.4% a year.
Context
- Total current liabilities amounted to 13.6% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -10.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 73.32M USD
- Year-over-year change
- +44.0%
- 3-year CAGR
- +76.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.32M | +44.0% |
| FY2024 | 2024-12-31 | 50.91M | +143.9% |
| FY2023 | 2023-12-31 | 20.87M | +56.3% |
| FY2022 | 2022-12-31 | 13.35M | — |
Total Current Liabilities vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -10.9% is the 8th highest of 9, against a peer median of +30.8%.
- Total current liabilities amounts to 13.6% of total assets for ALMS, versus a peer median of 13.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $89.49M USD | +34.3% | +15.0% | 17.7% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $76.23M USD | -10.9% | +76.4% | 13.6% |
| Mar 2026 | $41.7M USD | -5.3% | +14.0% | 12.6% | |
| Mar 2026 | $27.37M USD | +27.2% | +9.3% | 13.8% | |
| Mar 2026 | $24.33M USD | +70.3% | +21.9% | 36.6% | |
| Mar 2026 | $11.6M USD | +106.6% | -16.4% | 11.6% | |
| Mar 2026 | €11.4M EUR | -29.6% | -0.1% | 23.3% | |
| Dec 2025 | $11.21M USD | +52.5% | +18.9% | 97.5% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.88M USD | -10.8% | -20.1% | 10.3% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €9.51M EUR | — | — | 5.7% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +30.8% | +11.7% | 13.8% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.